| Name | Title | Contact Details |
|---|
Adolescent AIDS Program is a Hastings, NE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Health Innovations is a Phoenix, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Sandra Heath and Associates is a Cleveland, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Over 26 million Americans suffer from chronic kidney disease (CKD), including 1.5 million New Yorkers. Formed in 1972 as a philanthropic gift of Edwin and Rhoda Sperber, the Foundation provides services to patients, family members, the general public and clinical and academic professionals throughout the Northeast. The mission of the Northeast Kidney Foundation is to improve the quality of life of those affected by kidney disease and related conditions through early identification, intervention, prevention and support services; to promote organ donation; and to empower those we serve to be an effective voice for better healthcare at the local, state and federal levels.
Kymera is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. Kymera’s proprietary targeted protein degradation platform, called Pegasus, enables us to discover highly selective small molecule protein degraders with activity against disease-causing proteins throughout the body. We believe that our small molecule protein degraders have significant advantages over existing therapies and allow us to address a large portion of the human genome that was previously intractable with traditional modalities. Kymera focuses on biological pathways that have been clinically validated but where key biological nodes/proteins have not been drugged or have been inadequately drugged. To date, we have utilized our Pegasus platform to design novel protein degraders focused in the areas of immunology-inflammation and oncology, and continue to apply our platform’s capabilities to additional therapeutic areas.